Table II.

Characteristics of patients during the aspirin challenge before and after surgery.

	Before surgery	After surgery	P-value
Baseline FEV1, % predicted (±SEM)	83.7 ± 4.3	83.9 ± 4.3	0.9
Number of patients with no clinical symptoms during aspirin challenge, N (%)	0	12 (43)	<0.001
Decrease in FEV1-% predicted during hypersensitivity reaction to aspirin, % median (IQR)	−10.0 (−19.0 to −3.8)	−8.6 (−14.0 to −2.4)	0.02
Minimal FEV1-% value during hypersensitivity reaction to aspirin, % (±SEM)	68.0 ± 3.9	78.0 ± 4.9	0.04
Baseline nasal peak flow, L/min (±SEM)	107.0 ± 8.6	141.0 ± 9.0	0.003
Decrease in nasal peak flow, % median (IQR)	−26 (−45 to −16)	−13 (−20 to 4)	0.001
Minimal nasal peak flow during hypersensitivity reaction to aspirin, L/min, median (IQR)	80 (30–100)	130 (90–170)	<0.001
FeNO*, ppb median (IQR)	45 (28–69)	28 (16–44)	0.006
FeNO decrease during aspirin desensitization, % median (IQR)	−23 (−41 to −17)	−13 (−32 to −2)	0.04
Time in minutes to the onset of the hypersensitivity reaction after provoking dose, mean (±SEM)	43 (± 5.7)	38 (± 5.0)	0.5
Number of aspirin doses before hypersensitivity reaction onset, median (IQR)	2 (1–2)	2 (1–2)	0.8
Aspirin provoking dose (mg), median (IQR)	80 (40–80)	80 (40–80)	0.5
Number of aspirin doses before hypersensitivity reaction onset, median (IQR)	2 (1–2)	2 (1–2)	0.8
Baseline peripheral blood eosinophil counts, K/μL, median (IQR)	0.7 (0.4–0.8)	0.3 (0.1–0.5)	0.003

^*FeNO = fractioned exhaled nitric oxide